Dr. Rezvani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Drive
Stanford, CA 94305Phone+1 650-723-0822- Is this information wrong?
Summary
- I am a physician and clinical researcher at Stanford University, specializing in hematopoietic cell transplantation and cellular therapy.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2001
Certifications & Licensure
CA State Medical License 2014 - 2025
WA State Medical License 2004 - 2015
NC State Medical License 2001 - 2004- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 2006 Dec 01
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2009 Feb 01
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.Rezvani, A. R., Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Parveen Shiraz, Neha Agarwal, Mark Hamilton, Courtney Erickson, ...> ;Leukemia. 2024 May 1
- Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.Rezvani, A. R., Cameron S Bader, Anna Pavlova, Robert Lowsky, Lori S Muffly, Parveen Shiraz, Sally Arai, Laura J Johnston, Andrew R Rezvani, Wen-Kai Weng, David B Mikl...> ;Blood Advances. 2024 Mar 12
- 5 citationsASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.Zurko, J. C., Rezvani, A. R., Narendranath Epperla, Ambuj Kumar, Syed A Abutalib, Farrukh T Awan, Yi-Bin Chen, Ajay K Gopal, Jennifer Holter-Chakrabarty, Natasha Kekre...> ;Transplantation and Cellular Therapy. 2023 Sep 1
- Join now to see all
Abstracts/Posters
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsAndrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021- Nevada Cancer Survivor Found to Have Two Different Sets of DNA After Bone Marrow Transplant 4 Years AgoDecember 10th, 2019
- After Bone Marrow Transplant, Patient's Blood Contains Only Donor's DNA: Three Months After a Nevada Man Received a Bone Marrow Transplant, Tests Revealed the DNA in His Blood Had Been Replaced by the DNA of His Donor, a Man He Barely Knew, According t...December 9th, 2019
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
